CAR-T: Τι είναι οι «γενετικές θεραπείες» για λευχαιμία και λέμφωμα
Η πρώτη συμφωνία στην Ευρώπη για νέα θεραπεία του καρκίνου
Beat you to it, Kymriah: Gilead strikes discount Yescarta deal with NHS in adults
NICE decision could limit future development of CAR T therapies;
CAR-T Therapies in 2018
Cell and Gene Therapy Tracker: Global CAR T-Cell Trials
By many standards, and certainly by the way the media covers it and industry promotes it, immuno-oncology therapies using CAR-T are revolutionizing cancer treatments. But what if, as the saying goes, they threw a revolution and nobody came? Or more precisely, what if they threw a revolution and no one was willing to pay for … Συνεχίστε να διαβάζετε Does CAR-T Therapy Have a Payment Problem?.
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs. It was pretty obvious four or five years ago that early work in immuno-oncology was going to have a huge effect, and it did, when in 2017 the U.S. Food and Drug … Συνεχίστε να διαβάζετε Taking a Look at Trends in Biotherapeutics.
2018 is already half over, but expect fireworks now that President Trump has turned his attention to seeking lower drug prices. The Tweeter-in-Chief publicly shamed companies that have tried to take the typical mid-year price increases. Without the usual bump in price, some companies are going to face stagnate growth to some of their biggest … Συνεχίστε να διαβάζετε 7 companies to watch during Q2 earnings.
The lowest-hanging fruits of chimeric antigen receptor (CAR) T-cell therapy are already being plucked. Yet even these fruits, which include Kite Pharma’s Yescarta and Novartis’ Kymriah, cannot be described as easy pickings. They obliged their developers to stretch their own capabilities while staying in touch with the latest research findings. Nonetheless, Yescarta and Kymriah, … Συνεχίστε να διαβάζετε CAR T Cells Show Solid Progress.